Floatz logo

Metformin

Nonsquamous Nonsmall Cell Neoplasm of Lung

Beth Israel Medical CenterSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Nonsquamous Nonsmall Cell Neoplasm of Lung cohort.

Asset / SponsorPhaseRating
Carboplatin
Arcus Biosciences, Inc.
Phase 2BB
CIS-DIAMMINEDICHLOROPLATINUM II
Intergroupe Francophone de Cancerologie Thoracique
Phase 2BB
Demcizumab
OncoMed Pharmaceuticals, Inc.
Phase 2B
Irinotecan
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B
(+)-VINCRISTINE
Intergroupe Francophone de Cancerologie Thoracique
Phase 2B

View all 20 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →